Cargando…

Hepatitis C virus eradication improves immediate and delayed episodic memory in patients treated with interferon and ribavirin

BACKGROUND: Chronic hepatitis C virus (HCV) infection is associated with impairment of cognitive function and mood disorders. Our aim was to evaluate the impact of sustained virological response (SVR) on cognitive function and mood disorders. METHOD: A prospective exploratory one arm study was condu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barbosa, Mary Ellen Dias, Zaninotto, Ana Luiza, de Campos Mazo, Daniel Ferraz, Pessoa, Mario Guimarães, de Oliveira, Cláudia Pinto Marques Souza, Carrilho, Flair José, Farias, Alberto Queiroz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702148/ https://www.ncbi.nlm.nih.gov/pubmed/29178838 http://dx.doi.org/10.1186/s12876-017-0679-5

Ejemplares similares

Lactose intolerance: diagnosis, genetic, and clinical factors
por: Mattar, Rejane, et al.
Publicado: (2012)

Accuracy of transient elastography-FibroScan(®), acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C
por: Ragazzo, Taisa Grotta, et al.
Publicado: (2017)

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
por: Abbas, Zaigham, et al.
Publicado: (2013)

Hepatitis E virus infection increases the risk of diabetes and severity of liver disease in patients with chronic hepatitis C virus infection
por: Zitelli, Patricia Momoyo Yoshimura, et al.
Publicado: (2021)

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
por: Gonçales, Fernando L, et al.
Publicado: (2010)

Clinical spectrum and therapeutic approach to hepatocellular injury in patients with hyperthyroidism
por: de Campos Mazo, Daniel Ferraz, et al.
Publicado: (2013)

Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
por: Akram, Madiha, et al.
Publicado: (2011)

Expectoration of Large Bronchial Casts Secondary to the Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin
por: de Araújo, Evaldo Stanislau Affonso, et al.
Publicado: (2010)

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ribavirin
por: Goodarzi, Navid, et al.
Publicado: (2016)

The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy
por: Nagaoki, Yuko, et al.
Publicado: (2017)

Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
por: Meyer, Douglas F., et al.
Publicado: (2010)

Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection
por: Kagawa, Tatehiro, et al.
Publicado: (2010)

Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea
por: Cho, Hyun Chin, et al.
Publicado: (2013)

Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
por: Carvalho-Filho, Roberto J, et al.
Publicado: (2010)

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy
por: Chopra, Amit, et al.
Publicado: (2015)

Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy
por: Pradat, Pierre, et al.
Publicado: (2015)

Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
por: Chak, Eric, et al.
Publicado: (2010)

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
por: Hartl, Janine, et al.
Publicado: (2012)

Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C
por: Aizawa, Nobuhiro, et al.
Publicado: (2013)

Successful treatment of psychosis induced by interferon alpha and ribavirin with paliperidone: first case reported
por: Carrillo de Albornoz Calahorro, Carmen Maura, et al.
Publicado: (2019)

Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens
por: Younossi, Zobair M., et al.
Publicado: (2016)

Nonarteritic anterior ischemic optic neuropathy associated with interferon and ribavirin in a patient with hepatitis C
por: Sharif, Walid, et al.
Publicado: (2016)

Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
por: Karino, Y, et al.
Publicado: (2014)

Cardiohepatic Interactions - from Humoral Theory to Organ Transplantation
por: Silvestre, Odilson Marcos, et al.
Publicado: (2014)

Terlipressin versus Norepinephrine in the Treatment of Hepatorenal Syndrome: A Systematic Review and Meta-Analysis
por: Nassar Junior, Antonio Paulo, et al.
Publicado: (2014)

Retreatment of hepatitis C non-responsive to Interferon. A placebo controlled randomized trial of Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]
por: Veldt, Bart J, et al.
Publicado: (2003)

Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin
por: Falzarano, Darryl, et al.
Publicado: (2013)

Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol
por: Zeng, Yan-Ming, et al.
Publicado: (2020)

Thyroid hormonal disturbances related to treatment of hepatitis C with interferon-alpha and ribavirin
por: Danilovic, Debora Lucia Seguro, et al.
Publicado: (2011)

354 Autoimmune Hepatitis Misdiagnosed as Hepatitis C Responding to Interferon/Ribavirine Therapy
por: Pijak, Michal R., et al.
Publicado: (2012)

Cutaneous side effects of combination therapy of pegylated interferon 2α and ribavirin
por: Raducan, Anca, et al.
Publicado: (2014)

Combination effects of ribavirin and interferons on severe fever with thrombocytopenia syndrome virus infection
por: Shimojima, Masayuki, et al.
Publicado: (2015)

Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin
por: Asselah, Tarik, et al.
Publicado: (2010)

The evolving role of interferons in viral eradication strategies
por: Doyle, Tomas
Publicado: (2016)

IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS
por: DRESCH, Kelly Fernanda Nomura, et al.
Publicado: (2016)

Ribavirin
Publicado: (2016)

Ribavirin
por: Hall, Caroline Breese
Publicado: (1985)

Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study
por: Kovari, Helen, et al.
Publicado: (2015)

Longitudinal Study of a Human Drug-Induced Model of Autoantibody to Cytoplasmic Rods/Rings following HCV Therapy with Ribavirin and Interferon-α
por: Keppeke, Gerson Dierley, et al.
Publicado: (2012)

Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C
por: Rodríguez-Lojo, R., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ousnj3bcl4624b407ahglq4ics